OverT Bio Receives $120,000 GRex Grant from ScaleReady to Advance NextGeneration Cell Therapies
OverT Bio, an NYCbased cell therapy company, has been awarded a $120,000 GRex Grant from ScaleReadyTM, in collaboration with Wilson Wolf Manufacturing, BioTechne Corporation (NASDAQ: TECH), and CellReadyTM. This funding will support OverT Bios development of nextgeneration cell therapies for solid tumors, utilizing innovative datadriven discovery platforms OverTargetTM and OverTCRTM. “We are pleased to receive…